Santhera Releases Annual General Meeting Agenda
Pratteln, Switzerland, May 28, 2024 – Santhera Pharmaceuticals (SIX: SANN) has announced that its Annual General Meeting (AGM) will take place on June 18, 2024, at 10:00 CEST. The event will be held at Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, Switzerland. Registered shareholders will receive the official invitation along with the agenda items and explanations by mail, and these details will also be available on Santhera’s website.
AGM Agenda Overview
The meeting will cover key topics including:
1. Approval of the Annual Report, Financial Statements, and Consolidated Financial Statements for 2023.
2. Appropriation of the Annual Result and Offset of Deficit.
3. Consultative Vote on the Compensation Report for 2023.
4. Discharge of Board of Directors and Executive Management from Liability for the Financial Year 2023.
5. Amendments to the Articles of Incorporation.
6. Re-election of the Members of the Board of Directors and the Chairman of the Board.
7. Re-election of the Members of the Compensation Committee.
8. Approval of the Compensation for the Members of the Board of Directors.
9. Approval of the Compensation for the Members of the Executive Management.
10. Re-election of the Statutory Auditors.
11. Re-election of the Independent Proxy.
About Santhera Pharmaceuticals
Santhera Pharmaceuticals is a Swiss specialty pharmaceutical firm dedicated to developing and commercializing innovative treatments for rare neuromuscular and pulmonary diseases with significant unmet medical needs. The company has secured an exclusive global license from ReveraGen for all indications for AGAMREE® (vamorolone), a dissociative steroid with a unique mode of action. AGAMREE has been evaluated in a pivotal study for Duchenne muscular dystrophy (DMD) and is approved for DMD treatment by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the UK's Medicines and Healthcare products Regulatory Agency (MHRA).
Santhera has out-licensed the rights to market AGAMREE in North America to Catalyst Pharmaceuticals, Inc., and in China to Sperogenix Therapeutics.
Conclusion
Santhera Pharmaceuticals is set to hold its AGM on June 18, 2024, focusing on several critical agenda items, including financial approvals, compensation votes, and re-elections. The meeting will also provide updates on the company’s strategic directions and achievements, particularly concerning the development and commercialization of AGAMREE for DMD.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
